Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV

By Jiabao Xu, Shizhe Zhao, Tieshan Teng, A. E. Abdalla, Wan Zhu, Longxiang Xie, Yunlong Wang, Xiangqian Guo. Viruses, 2020

660 citations recorded by the source corpus.

After the outbreak of the severe acute respiratory syndrome (SARS) in the world in 2003, human coronaviruses (HCoVs) have been reported as pathogens that cause severe symptoms in respiratory tract infections. Recently, a new emerged HCoV isolated from the respiratory epithelium of unexplained pneumonia patients in the Wuhan seafood market caused a major disease outbreak and has been named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus causes acute lung symptoms, leading to a condition that has been named as “coronavirus disease 2019” (COVID-19). The emergence of SARS-CoV-2 and of SARS-CoV caused widespread fear and concern and has threatened global health security. There are some similarities and differences in the epidemiology and clinical features between these two viruses and diseases that are caused by these viruses. The goal of this work is to systematically review and compare between SARS-CoV and SARS-CoV-2 in the context of their virus incubation, originations, diagnosis and treatment methods, genomic and proteomic sequences, and pathogenic mechanisms.

Subfields: Animal Science and Zoology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/36b385c76d8e5834743c3b38a476718518600ec4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

S. Frank
Taj Mohammad
M. Hassan
J. Leuppi
Daniel Turek
S. Savic
Urooj Fatima
Kisa Fatima

Citations in the corpus

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach (2020, positive): “dicating a broad spectrum use of antiviral compounds designed against S2 domain of these viruses, which may be useful in COVID-19 therapy [15,64].”
Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction (2020, background): “This might be a major difference between infections caused by SARSCoV and SARS-CoV-2, the latter being more contagious but less virulent.(19) Autopsy studies on MERS are limited; according to our knowledge, there is currently only one complete autopsy case study described in the literature.”
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model (2020, background): “This is relatively slower than severe acute respiratory syndrome (SARS), which was caused by SARS-CoV (10).”